Information icon

💚 Start Your Weight Loss Journey From Just £74 | Use Code WL15 🌟

Weight Loss Injections
Complete our online consultation to start treatment in 4 simple & secure steps.
3 minute online consultation form
1. 3 minute online consultation form
Choose & pay for your medication
2. Choose & pay for your medication
Upload images for clinical review
3. Upload images for clinical review
Same day dispatch (order before 1pm)
4. Same day dispatch (order before 1pm)
  • UK-registered clinical team
    UK-registered clinical team
  • Confidential & secure
    Confidential & secure
  • No GP visit needed
    No GP visit needed
  • Fast & discreet delivery
    Fast & discreet delivery
Wegovy (semaglutide) injection 0.25mg Starter Dose 1 Pen Rear view of Wegovy Weight Loss Injections

Wegovy Weight Loss Injections

Wegovy Weight Loss Injections Product information

£88.96 (£88.96 per units)

Strength

Quantity

You need to complete a consultation before you can purchase this product.
Our Prices
0.25mg 0.5mg 1mg 1.7mg 2.4mg 7.2mg
1 units £88.96 £118.96 £128.96 £158.96 £188.96 £279.99
2 units - - - - £354.99 -

Wegovy Pen

Wegovy injections contain Semaglutide, a GLP-1 medication which minimises food cravings and helps you feel fuller for longer. It can be used as a longer term weight loss approach, including as part of a maintenance phase once you've reached your weight loss goal.

  • Lose up to 25% of starting bodyweight

  • Contains Semaglutide (a GLP-1 medication)

  • New 7.2mg strength now available

Time for a change?

Thinking about making the switch from Mounjaro to Wegovy? Explore our switching guide to see if it's right for you.

Choose to order with confidence at Oxford Online Pharmacy. Over 30,000+ patients have rated us 5 stars on Trustpilot.

Product Information for Wegovy Weight Loss Injections

Get to know the Wegovy Pen

Wegovy (Semaglutide) is licensed in the UK for weight loss and weight maintenance, used alongside a reduced-calorie diet and increased physical activity (1).

In a clinical trial, patients on the 7.2mg maintenance dose lost on average 19 to 21% of their starting body weight, with around 1 in 3 achieving over 25% (1-2). More than 9 out of 10 patients achieved clinically meaningful weight loss of 5% or more (2).

In a clinical trial, patients on 2.4mg maintenance dose lost on average 15-17% body weight reduction (vs 2.4% with placebo) (3).

Patients can reach a maintenance dose of 2.4 mg after a gradual 16-week dose escalation. For adults living with obesity (BMI of 30 or above), the dose can then be increased to 7.2 mg (administered as 3 injections of 2.4 mg) after a minimum of 4 weeks on 2.4 mg (1).

At the 2.4 mg maintenance dose, each pen is designed to last one month. Patients on the 7.2mg dose will require 3 doses of the 2.4mg pen per week (1).

Sourced direct from manufacturer (Novo Nordisk) (1).

Wegovy FlexTouch Pen key facts

Self-inject Wegovy at home once a week. Using its very fine needle, inject just under the skin in either your stomach area, thigh or upper arm – whichever you prefer.

Filled with 4 doses, each pen is designed to last a month (4x once weekly injections).

Always make sure to read the user instructions in the second half of the Patient Information Leaflet that comes with the pen.

How do Wegovy injections work?

Wegovy injections work by mimicking the GLP-1 (glucagon-like peptide-1) hormone your body naturally makes. This hormone targets brain areas involved in regulating appetite (hunger) and blood sugar. This can help you eat fewer calories and lose weight.

How Wegovy works with your body

Wegovy weight loss medication works with your body to help you lose weight, rather than against it. It’s most effective when used alongside a balanced, healthy diet and increased physical activity.

  • Minimises cravings: Wegovy can reduce food cravings (or food noise) for high-fat foods, helping you eat a more balanced and healthier diet.

  • Reduces blood sugar levels: When blood sugar levels are high (often after eating certain foods), it promotes the release of insulin to reduce blood sugar levels. This prevents excess sugar being stored as fat.

  • Makes you feel full: Wegovy works on the part of the brain that controls hunger, helping you feel full sooner and reducing how much you eat.

  • Slows digestion: Wegovy slows the speed at which food moves through the stomach, helping prevent blood sugar spokes after meals - keeping you feeling fuller. This helps reduce the urge to snack.

Understand who can use Wegovy

Wegovy might not be suitable for everyone. Our team follows strict clinical guidelines when assessing patients for treatment, including a thorough review of past medical history.

If you meet the criteria below, Wegovy may be a suitable treatment for you, but this isn’t guaranteed.

  • Adults aged 18-85 (clinical experience in patients over 75 is more limited)

  • Those with a BMI above 30 if you don’t have any weight-related health conditions

  • Those with a BMI above 27 and a weight-related condition such as high blood pressure, high cholesterol, heart disease, type 2 diabetes and some other health conditions

This list is only intended as in indicator for who might be suitable for treatment. The doctor will complete a full medical review of your consultation when considering you for treatment.

Use this NHS tool to calculate your BMI.

Who can’t use Wegovy?

Wegovy isn't suitable for everyone which is why our prescribers will review your full medical history during your consultation.

You shouldn't use Wegovy if you are allergic to Semaglutide or any of the other ingredients in the pen (disodium phosphate dihydrate, propylene glycol, phenol, sodium hydroxide or hydrochloric acid, water for injection).

You also shouldn't use Wegovy if you are pregnant, planning to become pregnant, or breastfeeding. If you're planning to conceive, you must stop taking Wegovy at least 2 months beforehand.

Any other health conditions that may require caution when taking Wegovy or specialist review will always be decided with your prescriber.

Weight loss results with Wegovy

The Wegovy FlexTouch pen comes in 6 dosage options. You’ll start weekly treatment on the lowest 0.25mg strength and gradually increase each month towards the 2.4mg strength, you can progress to the 7.2mg dose if your starting BMI was over 30. This step-by-step approach lets your body adapt to the medication gradually.

A range of studies have shown achievable weight loss of 5-20% with weekly Wegovy injections. Wegovy is a longer-term weight management treatment, and you should start to see weight loss within 4-6 weeks of starting treatment.  

Weight loss examples  

In a 2025 clinical trial, participants received either Wegovy 7.2 mg, Wegovy 2.4 mg, or placebo once weekly, alongside a reduced-calorie diet and increased physical activity. Results found:

Wegovy 7.2 mg at 72 weeks:

  • 19-21% average weight loss reduction

  • 90.7% of patients achieved weight loss of 5% or more

  • 47.7% of patients achieved weight loss of 20% or more

  • 31.2% of patients achieved weight loss of 25% or more

Wegovy 2.4 mg at 72 weeks:

  • 15-17% average weight loss reduction

  • 89.9% of patients achieved weight loss of 5% or more

  • 33.3% of patients achieved weight loss of 20% or more

  • 15.3% of patients achieved weight loss of 25% or more

Remember, studies are an indicator of what may be achieved and based on perfect adherence to diet, exercise and accurate dosing. Every weight loss journey is unique and might not happen as detailed above.

Our expert team is on-hand to help support your weight journey and give you advice on how to lose weight meaningfully and safely.

What are the cardiovascular benefits of Wegovy?

Beyond the weight loss benefits, Wegovy also has a separate licensed indication for reducing the risk of major adverse cardiovascular events, when used alongside a reduced-calorie diet and increased physical activity.

In a clinical trial comparing participants receiving Wegovy 2.4mg vs placebo, results showed a:

  • 20% reduction in major adverse cardiovascular events (CV death, non-fatal heart attack, or non-fatal stroke)

  • 28% reduction in fatal or non-fatal heart attack

  • 19% reduction in all-cause mortality

  • Reductions in blood pressure, waist circumference, and cholesterol at 104 weeks

For people with obesity or overweight who already have heart disease, Wegovy can directly reduce the risk of life-threatening cardiovascular events (14). Wegovy is not a substitute for existing heart medications, so consultation with your doctor or prescriber is always required.

Advisory information

For menopausal women taking HRT, you should consider changing oral oestrogen to transdermal oestrogen and also increasing dose of progesterone for 4 weeks after initiation of a GLP-1 or after any dose change. You should discuss this further with your GP or prescribing Doctor.

For women using oral contraceptives, based on current evidence, Wegovy (Semaglutide) does not reduce the effectiveness of oral contraceptives. Research has shown that Semaglutide doesn't significantly affect how well birth control pills are absorbed or work in your body.

While Wegovy itself doesn't interfere with contraceptive effectiveness, common side effects like vomiting or diarrhea can affect oral contraception. If you vomit within 3-4 hours of taking your pill or experience severe diarrhea, the hormones may not be fully absorbed. In these cases, you should use backup contraception (like condoms) until you've been symptom-free for about a week.

Wegovy is not suitable if you are planning to get pregnant, pregnant or breastfeeding. If you are planning on getting pregnant, make sure you have completely stopped using Wegovy at least 2 months before trying to conceive. Women of childbearing age should be on some form of contraception as the effects on the foetus are not yet known. If you have any concerns, speak to a healthcare professional.

If you have any concerns, speak to our team or a healthcare professional.

Wegovy Weight Loss Injections reviews

How to use Wegovy Weight Loss Injections

Always use the Wegovy FlexTouch Pen safely and as directed in the Patient Information Leaflet that comes with the pen. Follow medical advice from trained professionals and verified resources only.

Wegovy dose schedule

This medicine comes in different doses, and you must follow these dosage instructions:

Start with 0.25mg for the first 4 weeks. Then, the dose can be increased over consecutive months to 0.5mg, 1mg, 1.7mg, 2.4mg and then 7.2mg as tolerated. This gradual monthly increase should reduce the risk of unwanted side effects.

If any side effects last more than a few weeks after the dose increase, or become serious, contact our healthcare team.  

Possible dose schedule:

  • Weeks 1 - 4: Wegovy 0.25mg

  • Weeks 5 - 8: Wegovy 0.5mg

  • Weeks 9 - 12: Wegovy 1mg

  • Weeks 13 - 16: Wegovy 1.7mg

  • Weeks 17 - 20: Wegovy 2.4mg

  • Weeks 21 onward: Wegovy 7.2mg*

*Wegovy 7.2mg is only appropriate for those with a starting BMI over 30, even alongside other health conditions

Wegovy FlexTouch delivery and storage

As of April 2026, the Wegovy FlexTouch Pen can now be delivered without ice packs. The MHRA (Medicines and Healthcare products Regulatory Authority) has now approved the delivery of Wegovy in the UK at a temperature below 30°C for up to 48 hours.

Once received it is preferable to store your pen in your fridge (between 2°C to 8°C) as soon as possible after delivery. It should then be kept refrigerated until you open it to administer the first injection. Once opened, it can be stored at room temperature (up to 30°C) for up to 6 weeks. Always keep it out of direct sunlight and direct heat sources.

When travelling, your FlexTouch pen can be kept at room temperature (up to 30°C) for 6 weeks or you can use a cool bag with an ice pack, where needed. Never pack in your plane hold luggage as the medication may freeze, leaving it unusable.

How to inject Wegovy

It’s normal to be anxious the first time you’re getting ready to inject, but with preparation and practice it’ll become second nature.  

Three key stages to injecting include:

  1. Preparing your dose

  2. Injecting your dose

  3. Post-injection

Make sure to thoroughly read and understand the user instructions in the second half of the Patient Information Leaflet that comes with the FlexTouch Pen.

Our top injection tips include:

  • Reading the user instructions thoroughly

  • Washing your hands before starting

  • Choosing your injection site carefully to avoid side effects

  • Giving yourself plenty of time on your injection day so you aren’t rushed

Using Wegovy 7.2mg (3 x 2.4mg FlexTouch Pens)

If you are still receiving three 2.4mg pens for your 7.2mg dose you will inject three doses of 2.4mg one after each other. The injections can be given in the same body area, like the tummy or thigh, but should be at least 5 cm apart. The needle should be changed between each dose.

If you keep your pen in its original box, you will see four small tick boxes on the back. These are usually ticked off once per week so you know how many doses are left in the pen.

Instead with 7.2mg, we recommend you tick one box after each injection.

This helps you keep track and avoids taking too few or too many doses each week.

Side effects of Wegovy Weight Loss Injections

Below we’ve listed some common and some serious side effects, this list is not exhaustive. You should always read the Patient Information Leaflet that comes with your medication.

This will usually be in the medication packaging or box, but you can also read it online.  

See the Wegovy Patient Information Leaflet.

Common side effects

Side effects can be more common when starting Wegovy, or when increasing your dose. These side effects may affect more than 1 in 10 people who use this treatment.

  • Nausea

  • Diarrhoea

  • Vomiting

  • Constipation

  • Stomach (abdomen) pain

  • Headache

  • Tiredness (fatigue)

  • Temporary hair loss

  • Vision changes

Vision changes

Most people using Wegovy don't experience vision problems, though temporary blurred vision can occur in the first few weeks due to blood sugar changes as your body adjusts to treatment. For those with type 2 diabetes and existing Diabetic Retinopathy, rapid blood sugar improvements can occasionally trigger a flare-up.

If you experience sudden or painful changes to your vision, or changes that don’t ease after a few days, pause treatment and seek a same-day appointment with your optician, or call NHS 111 for out-of-hours care.

Serious side effects

If you experience any of the following types of serious side effects, stop taking Wegovy and contact your doctor immediately:

Uncommon side effects (may affect up to 1 in 100 people)

  • Inflamed pancreas (acute pancreatitis) which could cause severe pain in the stomach and back which does not go away. You should see a doctor immediately if you experience such symptoms. 

  • Kidney or bladder stones. Signs may include back or lower abdomen pain, difficulty in urination or change in colour of your urine.

Rare side effects (may affect up to 1 in 1000 people)

  • Severe allergic reactions (eg anaphylactic reaction, angioedema). You should get immediate medical help and inform your doctor if you experience symptoms such as breathing problems, rapid swelling of the lips, tongue and/or throat with difficulty swallowing and a fast heartbeat.

The complete range of side effects are listed in the Wegovy FlexTouch Pen Patient Information Leaflet. Not everyone will experience side effects, but this doesn’t mean the medication isn’t working.  

If you would like to talk to our Healthcare Advisors about any concerns around side-effects please call us on 01295 262925 or email help@oxfordop.co.uk

Pancreatitis

  • Pancreatitis (inflammation of the pancreas) is a possible side effect with GLP-1 receptor agonists and dual GLP-1/ GIP receptor agonists.

  • In rare reports this can have serious or fatal outcomes

  • Seek urgent medical attention if you experience severe, persistent abdominal pain, that may radiate to your back and may be accompanied by nausea and vomiting, as this may be a sign of pancreatitis

  • Do not restart GLP-1 receptor agonist or GLP-1/GIP receptor agonist treatment if pancreatitis is confirmed

  • Report suspected side effects through the Yellow Card scheme

Frequently Asked Questions
Patient Information Leaflet

Important - Before taking any medication, it is always important to read the Patient Information Leaflet (PIL)

Wegovy Weight Loss Injections - Patient Information Leaflet

References
  1. Novo Nordisk Limited (2025) Wegovy (semaglutide) Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/13799/smpc (Accessed: April 2026).

  2. Wharton, S. et al. (2025) 'Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial', The Lancet Diabetes & Endocrinology, S2213-8587(25), pp. 00226-8. Available from: https://pubmed.ncbi.nlm.nih.gov/40961952/. Retrieved April 17, 2026.

  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. Available from:

    https://www.nejm.org/doi/full/10.1056/NEJMoa2032183. Retrieved April 17, 2026.

  4. Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Network Open [Internet]. 2022;5(9):e2231982. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486455/. Retrieved December 3, 2025.

  5. Wilding JPH, Batterham RL, Calanna S. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine [Internet]. 2021 Feb 10;384(11):989–1002. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183. Retrieved December 3, 2025.

  6. James D. STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo [Internet]. Applied Clinical Trials. 2025. Available from: https://www.appliedclinicaltrialsonline.com/view/step-up-trial-semaglutide-superior-weight-loss. Retrieved December 3, 2025.

  7. Moiz A, Levett JY, Filion KB, Peri K, Reynier P, Eisenberg MJ. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. The American Journal of Cardiology [Internet]. 2024 Apr 26;222:121–30. Available from: https://pubmed.ncbi.nlm.nih.gov/38679221. Retrieved December 3, 2025.

  8. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine [Internet]. 2022 Jun 4;387(3). Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038. Retrieved December 3, 2025.

  9. Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. The Journal of Clinical Pharmacology. 2015 Jan 14;55(5):497–504. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4418331/. Retrieved December 3, 2025.

  10. Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine. 2022 Oct 1;28(10):2083–91. Available from: https://www.nature.com/articles/s41591-022-02026-4. Retrieved December 3, 2025.

  11. GB -Wegovy PIL-Version 7 [Internet]. Available from: https://www.medicines.org.uk/emc/files/pil.13799.pdf. Retrieved December 3, 2025.

  12. Wegovy 1 mg, FlexTouch solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc) [Internet]. www.medicines.org.uk. Available from: https://www.medicines.org.uk/emc/product/13801/smpc#gref. Retrieved December 3, 2025.

  13. Mitri J. Wegovy side effects: What you should know [Internet]. Medicalnewstoday.com. Medical News Today; 2022. Available from: https://www.medicalnewstoday.com/articles/drugs-wegovy-side-effects#more-common-side-effects. Retrieved December 3, 2025.

  14. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al.; for the SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221–2232. DOI: 10.1056/NEJMoa2307563

  15. Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, Hjelmesæth J, Hoffmann Morville T, et al.; for the STEP 9 Study Group. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 2024;391(17):1573–1583. DOI: 10.1056/NEJMoa2403664

Message From Our Pharmacist

Some people taking GLP-1 injections for weight loss have reported temporary blurred vision. This can happen during the first few weeks of treatment and is usually due to changes in blood sugar levels, or dry eyes caused by dehydration.

There’s usually nothing to worry about, but if you experience any sudden or severe changes to your vision, contact your optician immediately (NHS 111 for out-of-hours) and let them know you’re taking a GLP-1 weight loss medication.

Related Weight Loss Injections Articles
More...

Authored on February 10, 2026

Reviewed on February 10, 2026

Kiran Jones

Kiran Jones - MPharm, MRPharmS

Pharmacist / Medical Content Writer

GPhC Number: 2071585